Development and Validation of UV-Visible Spectrophotometric Baseline Manipulation Method for Simultaneous Quantitation of Tenofovir Disoproxil Fumarate and Emtricitabine in Pharmaceutical Dosage Form | Zendy

Vishnu P. Choudhari | Zendy; Sanket R. Parekar | Zendy; Subhash G. Chate | Zendy; Pradeep D. Bharande | Zendy; Rajiv Singh | Zendy; Bhanudas S. Kuchekar | Zendy

Open Access

Development and Validation of UV-Visible Spectrophotometric Baseline Manipulation Method for Simultaneous Quantitation of Tenofovir Disoproxil Fumarate and Emtricitabine in Pharmaceutical Dosage Form

Author(s) -

Vishnu P. Choudhari,

Sanket R. Parekar,

Subhash G. Chate,

Pradeep D. Bharande,

Rajiv Singh,

Bhanudas S. Kuchekar

Publication year - 2012

Publication title -

journal of spectroscopy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.323

H-Index - 21

eISSN - 2314-4920

pISSN - 2314-4939

DOI - 10.1155/2013/146580

Subject(s) - emtricitabine , tenofovir , dosage form , chromatography , distilled water , chemistry , ultraviolet visible spectroscopy , beer–lambert law , solvent , medicine , human immunodeficiency virus (hiv) , optics , physics , antiretroviral therapy , organic chemistry , viral load , family medicine

A simple, economical, precise, and accurate new UV-visible spectrophotometric baseline manipulation method for simultaneous determination of tenofovir disoproxil fumarate (TE) and emtricitabine (EM) in combined tablet dosage form has been developed. The method is based on baseline manipulation (difference) spectroscopy where amplitudes at 261 and 289.9 nm were selected to determine TE and EM, respectively, in combined formulation, and distilled water was used as solvent. Both drugs obey Beer’s law in the concentration ranges of 4–20 μg/mL for TE and 6–30 μg/mL for EM. The results of analysis have been validated statistically, and recovery studies confirmed the accuracy of the proposed method which was carried out by following the ICH guidelines

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research